{"data":{"id":1777,"lang":"en","title":"AI-Designed 'Universal' Coronavirus Vaccine Passes First Human Trial, Aiming to Stop Pandemics Before They Start","summary":"A Cambridge AI-designed DNA vaccine targeting whole families of coronaviruses passed its first human trial, proving safe in 39 volunteers and triggering broad immunity.","category":"science","category_label":"Science","published_at":"2026-06-05T14:02:19Z","updated_at":"2026-06-05T14:02:19Z","url":"https://techtools.cz/tools/news/article/1777-ai-designed-universal-coronavirus-vaccine-passes-first-human-trial-aiming-to","api_url":"https://techtools.cz/news-api/v1/articles/1777?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/1777.md?lang=en","image_url":"https://www.thenationalnews.com/resizer/v2/4OJQN4X7YTOFUA6MX7O3IDGQ64.jpg?smart=true\u0026auth=30253513ddf8cfcc1fd7b556d3c722ad162afaf8c3f86530e3cd320e0c7a9dbc\u0026width=400\u0026height=225","word_count":182,"reading_time_minutes":1,"sources":[{"url":"https://www.cam.ac.uk/research/news/new-universal-vaccine-technology-could-protect-us-from-future-virus-outbreaks","domain":"cam.ac.uk"},{"url":"https://www.news-medical.net/news/20260604/Universal-Sarbeco-coronavirus-vaccine-proves-safe-in-first-human-trial.aspx","domain":"news-medical.net"},{"url":"https://www.thenationalnews.com/health/2026/06/04/ai-designed-vaccine-could-prevent-pandemics-before-they-begin/","domain":"thenationalnews.com"}],"translation":{"lang":"cs","id":1850,"title":"Univerzální vakcína proti koronavirům navržená umělou inteligencí prošla prvním testem na lidech, má zastavit pandemie dřív, než začnou","url":"https://techtools.cz/tools/news/clanek/1850-univerzalni-vakcina-proti-koronavirum-navrzena-umelou-inteligenci-prosla-prvnim","api_url":"https://techtools.cz/news-api/v1/articles/1850?lang=cs"},"content":"A vaccine designed by artificial intelligence to protect against entire families of coronaviruses has passed its first human safety trial, scientists at the University of Cambridge and spin-out DIOSynVax announced. The Phase I trial gave the needle-free DNA vaccine to 39 healthy volunteers aged 18 to 50 in Cambridge and Southampton and found it safe with no significant side-effects, with results published in the Journal of Infection.\n\nRather than targeting a single virus, the team used machine learning to scan global genetic data from the Sarbecovirus group and identify structural features shared across the whole family. They then engineered a synthetic 'super-antigen' carrying those common traits. In volunteers the shot triggered immune responses not only to SARS-CoV-2 and the original SARS virus, but to related bat viruses that have not yet jumped to humans.\n\n\"We've converted vaccine development from being reactive to being future proof,\" said lead researcher Professor Jonathan Heeney, arguing that pre-developing such vaccines before an outbreak could save millions of lives. A larger Phase II study is now being planned, with more than 200 people set to be recruited."}}